EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., a biotechnology company at the forefront of research into the potential medical and aesthetic use of fibroblasts, plans to initiate a Phase II clinical trial to assess the potential of azficel-T for treating restrictive burn scars in first quarter, 2013. Fibroblasts are skin cells responsible for the production of collagen that contribute to the formation of connective tissue fibers. The company recently launched LAVIV® (azficel-T), the first and only personalized cell treatment approved by the FDA to improve the appearance of moderate to severe nasolabial folds or “smile line” wrinkles in adults.
